Patents by Inventor Rahul Kakkar

Rahul Kakkar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250129151
    Abstract: Methods for treating hepcidin-mediated disorders are provided.
    Type: Application
    Filed: December 23, 2024
    Publication date: April 24, 2025
    Inventors: Rahul Kakkar, Madhav N. Devalaraja, Katherine Jane Escott
  • Publication number: 20250057980
    Abstract: The present disclosure provides compositions, methods, and an overall platform for co-delivery of gene editor polynucleotides and template polynucleotides. The gene editor polynucleotide packaged in a LNP is co-delivered with a template polynucleotide (i.e., “cargo” or “payload”) packaged into a separate vector that is capable of localizing the donor template to a cell nucleus. In certain embodiments, the donor template vector is an AAV, a helper dependent adenovirus, or an integration deficient lentivirus. In typical embodiments, the template polynucleotide is integrated into the genomic integration recognition site by an integrase, optionally by an integrase fused/linked to a gene editor protein.
    Type: Application
    Filed: December 22, 2022
    Publication date: February 20, 2025
    Inventors: Jonathan Douglas Finn, Rahul Kakkar, Xin Jenny Xie, Brett Joseph Gordon Estes
  • Publication number: 20230287105
    Abstract: The disclosure provides methods of treating cardivascular disease, including pateints with atherosclerotic cardiovascular disease and/or chronic kidney disease. The method comprises administering a therapeutically effective amount of ziltivekimab.
    Type: Application
    Filed: July 9, 2021
    Publication date: September 14, 2023
    Inventors: Madhav N. Devalaraja, Michael H. Davidson, Rahul Kakkar
  • Publication number: 20230090473
    Abstract: The disclosure provides methods of treating inflammation without inducing immune suppression. The method comprises administering a therapeutically effective amount of an IL-6 antagonist at a dose sufficient to reduce inflammation without causing immune suppression.
    Type: Application
    Filed: November 22, 2022
    Publication date: March 23, 2023
    Inventors: Madhav N. Devalaraja, Michael H. Davidson, Rahul Kakkar
  • Publication number: 20220227856
    Abstract: The disclosure provides methods of treating inflammation without inducing immune suppression. The method comprises administering a therapeutically effective amount of an IL-6 antagonist at a dose sufficient to reduce inflammation without causing immune suppression.
    Type: Application
    Filed: March 30, 2022
    Publication date: July 21, 2022
    Inventors: Madhav N. Devalaraja, Michael H. Davidson, Rahul Kakkar
  • Patent number: 11384143
    Abstract: The disclosure provides methods of treating inflammation without inducing immune suppression. The method comprises administering a therapeutically effective amount of an IL-6 antagonist at a dose sufficient to reduce inflammation without causing immune suppression.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: July 12, 2022
    Assignee: NOVO NORDISK A/S
    Inventors: Madhav N. Devalaraja, Michael H. Davidson, Rahul Kakkar
  • Publication number: 20220195033
    Abstract: The present disclosure provides methods of treating diuretic resistance by administering an IL-6 antagonist to patients who require diuresis. In typical embodiments, the patient has heart failure. Optionally, the patient has elevated urine levels of IL-6, plasma levels of IL-6, or both urine and plasma levels of IL-6.
    Type: Application
    Filed: November 4, 2021
    Publication date: June 23, 2022
    Inventors: Jeffrey TESTANI, Veena RAO, Rahul KAKKAR, Madhav N. DEVALARAJA, Chih-Hung LO
  • Patent number: 11203636
    Abstract: The present disclosure provides methods of treating diuretic resistance by administering an IL-6 antagonist to patients who require diuresis. In typical embodiments, the patient has heart failure. Optionally, the patient has elevated urine levels of IL-6, plasma levels of IL-6, or both urine and plasma levels of IL-6.
    Type: Grant
    Filed: February 1, 2018
    Date of Patent: December 21, 2021
    Assignees: YALE UNIVERSITY, Novo Nordisk A/S
    Inventors: Jeffrey Testani, Veena Rao, Rahul Kakkar, Madhav N. Devalaraja, Chih-Hung Lo
  • Publication number: 20210292405
    Abstract: Methods for treating hepcidin-mediated disorders are provided.
    Type: Application
    Filed: March 9, 2021
    Publication date: September 23, 2021
    Inventors: Rahul KAKKAR, Madhav N. DEVALARAJA, Katherine Jane ESCOTT
  • Publication number: 20200079846
    Abstract: The present disclosure provides methods of treating diuretic resistance by administering an IL-6 antagonist to patients who require diuresis. In typical embodiments, the patient has heart failure. Optionally, the patient has elevated urine levels of IL-6, plasma levels of IL-6, or both urine and plasma levels of IL-6.
    Type: Application
    Filed: February 1, 2018
    Publication date: March 12, 2020
    Inventors: Jeffrey TESTANI,, Veena RAO, Rahul KAKKAR, Madhav N. DEVALARAJA, Chih-Hung LO
  • Publication number: 20190248886
    Abstract: The disclosure provides methods of treating inflammation without inducing immune suppression. The method comprises administering a therapeutically effective amount of an IL-6 antagonist at a dose sufficient to reduce inflammation without causing immune suppression.
    Type: Application
    Filed: April 26, 2019
    Publication date: August 15, 2019
    Inventors: Madhav N. Devalaraja, Michael H. Davidson, Rahul Kakkar
  • Publication number: 20190241650
    Abstract: The disclosure provides methods of treating inflammation without inducing immune suppression. The method comprises administering a therapeutically effective amount of an IL-6 antagonist at a dose sufficient to reduce inflammation without causing immune suppression.
    Type: Application
    Filed: January 4, 2019
    Publication date: August 8, 2019
    Inventors: Madhav N. Devalaraja, Michael H. Davidson, Rahul Kakkar
  • Publication number: 20170157109
    Abstract: A method for treating polycystic ovarian syndrome and related conditions with a compound (I): or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 16, 2016
    Publication date: June 8, 2017
    Inventors: Peter Stewart Gilmour, Tony Ho, Rahul Kakkar, Lorraine Webber
  • Publication number: 20170029499
    Abstract: Methods for treating hepcidin-mediated disorders are provided.
    Type: Application
    Filed: July 28, 2016
    Publication date: February 2, 2017
    Inventors: Rahul Kakkar, Madhav N. Devalaraja, Katherine Jane Escott
  • Patent number: 9475773
    Abstract: A method for treating polycystic ovarian syndrome and related conditions with a compound (I): or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 14, 2014
    Date of Patent: October 25, 2016
    Assignee: ASTRAZENECA AB
    Inventors: Peter Stewart Gilmour, Tony Ho, Rahul Kakkar, Lorraine Webber
  • Publication number: 20160089089
    Abstract: The system described herein collects patient data passively and non-passively via onboard and external sensors, and combines the data with past clinical history to generate digital biomarkers. The collected data can also be further combined with other data generating systems to more accurately predict disease exacerbations. The system monitors the digital biomarkers in real-time, and can detect a change in the disease state prior to clinical decompensation and suggest pre-emptive intervention. The system enables a patient to be treated early in the clinical timeline when the disease exacerbation is at the subclinical level rather than waiting until the disease exacerbation reaches the clinical level. Acting when the exacerbation is at the subclinical level enables preemptive treatment rather than reactive treatment, which is often more cost effective while improving clinical outcomes.
    Type: Application
    Filed: September 24, 2015
    Publication date: March 31, 2016
    Inventors: Rahul Kakkar, Cyan Collier, Hitesh Sanganee
  • Publication number: 20160083350
    Abstract: A method for treating polycystic ovarian syndrome and related conditions with a compound (I): or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 14, 2014
    Publication date: March 24, 2016
    Inventors: Peter Stewart Gilmour, Tony Ho, Rahul Kakkar, Lorraine Webber